Worth Watching: Insys Therapeutics Inc on Focus After Raising In Today’s Session

Worth Watching: Insys Therapeutics Inc on Focus After Raising In Today's Session

The stock of Insys Therapeutics Inc (NASDAQ:INSY) is a huge mover today! About 391,718 shares traded hands. Insys Therapeutics Inc (NASDAQ:INSY) has declined 21.15% since April 22, 2016 and is downtrending. It has underperformed by 26.56% the S&P500.
The move comes after 9 months positive chart setup for the $981.34 million company. It was reported on Nov, 25 by Barchart.com. We have $14.00 PT which if reached, will make NASDAQ:INSY worth $58.88 million more.

Analysts await Insys Therapeutics Inc (NASDAQ:INSY) to report earnings on February, 28. They expect $0.01 earnings per share, down 95.45% or $0.21 from last year’s $0.22 per share. INSY’s profit will be $742,877 for 330.25 P/E if the $0.01 EPS becomes a reality.

Insys Therapeutics Inc (NASDAQ:INSY) Ratings Coverage

Out of 4 analysts covering Insys Therapeutics (NASDAQ:INSY), 4 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Insys Therapeutics has been the topic of 9 analyst reports since August 4, 2015 according to StockzIntelligence Inc. On Tuesday, August 4 the stock rating was maintained by Oppenheimer with “Hold”. Jefferies maintained the stock with “Buy” rating in Thursday, August 4 report. The firm earned “Buy” rating on Thursday, April 14 by Janney Capital. Jefferies maintained Insys Therapeutics Inc (NASDAQ:INSY) rating on Monday, October 10. Jefferies has “Buy” rating and $18 price target. The firm has “Buy” rating by Zacks given on Friday, August 14. Jefferies maintained the stock with “Buy” rating in Tuesday, April 12 report. The company was maintained on Thursday, September 22 by RBC Capital Markets. JMP Securities maintained the shares of INSY in a report on Wednesday, March 9 with “Market Outperform” rating. The rating was maintained by Jefferies with “Buy” on Wednesday, February 24.

According to Zacks Investment Research, “Insys Therapeutics, Inc. is a commercial-stage specialty pharmaceutical company. It is engaged in the development and commercialization of pharmaceutical products that target the unmet needs of cancer patients, with an initial focus on cancer-supportive care. The company’s cancer-supportive care and cancer therapy product candidates include Fentanyl sublingual spray and Dronabinol SG capsule. Insys Therapeutics, Inc. is based in Phoenix, Arizona.”

Insitutional Activity: The institutional sentiment increased to 1.23 in Q2 2016. Its up 0.53, from 0.7 in 2016Q1. The ratio improved, as 22 funds sold all Insys Therapeutics Inc shares owned while 42 reduced positions. 13 funds bought stakes while 32 increased positions. They now own 31.30 million shares or 9.76% less from 34.69 million shares in 2016Q1.
Qs Llc last reported 182,135 shares in the company. Orbimed Advsr Limited has 0.63% invested in the company for 4.69M shares. Dimensional Fund Advsrs Ltd Partnership holds 0% or 581,756 shares in its portfolio. Mckinley Capital Management Ltd Company Delaware owns 160,585 shares or 0.1% of their US portfolio. Fin Architects Inc owns 6 shares or 0% of their US portfolio. Blackrock Advsrs Ltd Liability Corporation holds 0% or 279,631 shares in its portfolio. Financial Bank Of New York Mellon accumulated 506,159 shares or 0% of the stock. Proshare Limited Liability holds 56,136 shares or 0.01% of its portfolio. Geode has 182,001 shares for 0% of their US portfolio. Bnp Paribas Arbitrage has invested 0% of its portfolio in Insys Therapeutics Inc (NASDAQ:INSY). Blackrock Mngmt Limited Liability holds 0% or 113,933 shares in its portfolio. Fmr Ltd Liability Corp holds 794,645 shares or 0% of its portfolio. Moreover, Legal And General Group Incorporated Public Ltd Liability has 0% invested in Insys Therapeutics Inc (NASDAQ:INSY) for 6,247 shares. The New York-based Millennium Mngmt Ltd has invested 0.01% in Insys Therapeutics Inc (NASDAQ:INSY). Bancorp Of Montreal Can holds 23,474 shares or 0% of its portfolio.

Insider Transactions: Since June 6, 2016, the stock had 2 buys, and 4 sales for $704,930 net activity. STANLEY THEODORE H sold $270,300 worth of Insys Therapeutics Inc (NASDAQ:INSY) on Tuesday, August 16. On Tuesday, August 9 the insider BRENNAN DANIEL sold $110,752. Shares for $107,489 were bought by MEYER STEVEN J. $105,853 worth of Insys Therapeutics Inc (NASDAQ:INSY) was bought by JOHN N KAPOOR TRUST DATED SEPTEMBER 20 1989 on Friday, August 12. FOURTEAU PATRICK sold $276,900 worth of Insys Therapeutics Inc (NASDAQ:INSY) on Thursday, August 11.

More notable recent Insys Therapeutics Inc (NASDAQ:INSY) news were published by: Fool.com which released: “Here’s Why Insys Therapeutics Inc. Fell 14.3% in April” on May 10, 2016, also Wsj.com with their article: “Fentanyl Billionaire Comes Under Fire as Death Toll Mounts From Prescription …” published on November 22, 2016, Forbes.com published: “FDA Approves Insys Therapeutics’ 2nd Cannabis-Based Drug” on July 05, 2016. More interesting news about Insys Therapeutics Inc (NASDAQ:INSY) were released by: Globenewswire.com and their article: “Insys Therapeutics Announces CEO Succession Plan” published on September 21, 2016 as well as Businessinsider.com‘s news article titled: “A pharmaceutical company is fighting marijuana legalization because it would …” with publication date: September 13, 2016.

INSY Company Profile

Insys Therapeutics, Inc., incorporated on June 15, 1990, is a commercial-stage specialty pharmaceutical company. The Firm develops and commercializes supportive care products. Subsys is the Company’s marketed product. Subsys is a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and is a single-use product that delivers fentanyl, an opioid analgesic, for transmucosal absorption underneath the tongue. The Firm markets Subsys through its field sales force focused on supportive care physicians in the United States.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment